SCHEMBL3335307

SCHEMBL3335307

O=C(O)[C@@H]1[C@@H](Cc2cccc(Cl)c2)C(=O)N1C(=O)Nc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TPSAB1 Q15661 4/20 0.54
TPSD1 Q9BZJ3 4/20 0.54
TPSG1 Q9NRR2 4/20 0.54
FAAH O00519 2/20 0.50
ALDH1A1 P00352 1/20 0.45
MAPT P10636 5/20 0.45
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
KDM4E B2RXH2 1/20 0.45
TSHR P16473 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
LMNA P02545 1/20 0.43
HTT P42858 1/20 0.43
GRIN2B Q13224 1/20 0.43
F11 P03951 3/20 0.42
PTGS2 P35354 1/20 0.41
P2RY1 P47900 1/20 0.40
TP53 P04637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4751699 0.79 F11 (0.62) TPSAB1TPSD1TPSG1F11
SCHEMBL13302756 0.79 F11 (0.62) TPSAB1TPSD1TPSG1F11
SCHEMBL3336016 0.78 FAAH (0.54) TPSAB1TPSD1TPSG1FAAHALDH1A1
SCHEMBL3335679 0.78 TPSAB1 (0.48) TPSAB1TPSD1TPSG1FAAHNPC1
SCHEMBL3336606 0.75 TPSAB1 (0.50) TPSAB1TPSD1TPSG1F11
SCHEMBL3338504 0.74 TPSAB1 (0.47) TPSAB1TPSD1TPSG1F11
Trifluoroacetic Acid SCHEMBL3330678 0.74 F11 (0.56) TPSAB1TPSD1TPSG1F11
SCHEMBL16997812 0.74 F11 (0.52) TPSAB1TPSD1TPSG1F11
SCHEMBL18476746 0.74 F11 (0.52) TPSAB1TPSD1TPSG1F11
SCHEMBL16997618 0.73 TPSAB1 (0.44) TPSAB1TPSD1TPSG1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100144698-A1 SUBSTITUTED AZETIDINONES DAIAMED (US) 2010-06-10 US disclosed
US-20090143351-A1 SUBSTITUTED AZETIDINONES DAIAMED (US) 2009-06-04 US disclosed
US-7501404-B2 Substituted azetidinones DAIMED (US) 2009-03-10 US disclosed
EP-1871741-A2 SUBSTITUTED AZETIDINONES Daiamed, Inc. (US) 2008-01-02 EP disclosed
US-20070105832-A1 Substituted azetidinones Cadrenal Therapeutics, Inc. 2007-05-10 US disclosed
WO-2006108039-A2 SUBSTITUTED AZETIDINONES DAIAMED, INC. (US) 2006-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105832-A1 Substituted azetidinones F2R, CPA3, CFD TPSAB1 14/4885TPSD1 24/4885TPSG1 30/4885
US-20100144698-A1 SUBSTITUTED AZETIDINONES F2R, CPA3, CFD TPSAB1 14/4885TPSD1 24/4885TPSG1 30/4885
US-20090143351-A1 SUBSTITUTED AZETIDINONES F2R, CPA3, CFD TPSAB1 14/4885TPSD1 24/4885TPSG1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.